Teva has established Global Specialty Medicines group as part of its strategic plan to optimize commercialization.
The company has named Dr. Rob Koremans as the president and CEO of Global Specialty Medicines.
Koremans will report to Teva Pharmaceutical Industries president and CEO Dr. Jeremy Levin and will continue to serve on Teva's executive committee.
Koremans held key roles at several companies such as Sanofi SA, Serono Group, Grunenthal, Sanofi group.
Teva develops, produces and markets affordable generic drugs in addition to specialty pharmaceuticals and active pharmaceutical ingredients.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/teva-establishes-global-specialty-medicines-group-250413
